skip to Main Content

Improving Survival in Pancreatic Cancer with Platinum-Based Chemotherapy

Newsfeed image, light gray text on dark gray background
A small study of adults with the most common form of pancreatic cancer adds to evidence that patients with BRCA1 or BRCA2 gene mutations long linked to a high risk of breast cancer have poorer overall survival rates than those without the mutations.

The same study also found that those with BRCA1 or BRCA2 had better survival rates with platinum-based chemotherapy, compared with similar patients who received other drugs or no chemotherapy.  Read more . . .

Back To Top